Table 2.
Concordance indices (95% CI) (C-index) and Brier scores with the null model in parentheses of PATHFx 3.0 algorithms by primary tumor histology in the validation cohort (n = 356)
| Factor | n | C-index | Brier score |
|---|---|---|---|
| 1-month survival prediction | |||
| Overall | 356 | 0.71 (0.58–0.84) | 0.04 (0.05) |
| Solid organ | 333 | 0.71 (0.58–0.84) | 0.05 (0.05) |
| Lung | 116 | 0.78 (0.61–0.94) | 0.05 (0.05) |
| Breast | 58 | 0.76 (NA) | 0.03 (0.03) |
| Liver | 37 | NA | NA |
| Hematologic malignancies | 23 | NA | NA |
| Kidney | 21 | 0.89 (0.67–1.00) | 0.06 (0.09) |
| Prostate | 19 | 0.81 (0.42–1.00) | 0.07 (0.09) |
| 3-month survival prediction | |||
| Overall | 356 | 0.66 (0.59–0.73) | 0.14 (0.16) |
| Solid organ | 333 | 0.65 (0.58–0.73) | 0.15 (0.16) |
| Lung | 116 | 0.71 (0.57–0.85) | 0.13 (0.16) |
| Breast | 58 | 0.57 (0.37–0.75) | 0.07 (0.07) |
| Liver | 37 | 0.58 (0.33–0.83) | 0.14 (0.14) |
| Hematologic malignancies | 23 | 0.65 (NA) | 0.05 (0.05) |
| Kidney | 21 | 0.89 (0.75–1.00) | 0.13 (0.19) |
| Prostate | 19 | 0.63 (0.35–0.93) | 0.20 (0.22) |
| 6-month survival prediction | |||
| Overall | 356 | 0.65 (0.59–0.71) | 0.20 (0.22) |
| Solid organ | 333 | 0.64 (0.58–0.71) | 0.21 (0.22) |
| Lung | 116 | 0.66 (0.56–0.77) | 0.21 (0.22) |
| Breast | 58 | 0.69 (0.58–0.80) | 0.11 (0.11) |
| Liver | 37 | 0.57 (0.34–0.81) | 0.16 (0.16) |
| Hematologic malignancies | 23 | 0.59 (0.26–0.91) | 0.16 (0.16) |
| Kidney | 21 | 0.87 (0.71–1.00) | 0.15 (0.24) |
| Prostate | 19 | 0.56 (0.27–0.84) | 0.24 (0.24) |
| 12-month survival prediction | |||
| Overall | 356 | 0.69 (0.64–0.75) | 0.22 (0.25) |
| Solid organ | 333 | 0.68 (0.62–0.74) | 0.22 (0.25) |
| Lung | 116 | 0.69 (0.59–0.79) | 0.22 (0.25) |
| Breast | 58 | 0.59 (0.43–0.75) | 0.17 (0.17) |
| Liver | 37 | 0.73 (0.56–0.91) | 0.21 (0.25) |
| Hematologic malignancies | 23 | 0.67 (0.43–0.91) | 0.19 (0.20) |
| Kidney | 21 | 0.76 (0.53–0.99) | 0.19 (0.25) |
| Prostate | 19 | 0.53 (0.22–0.85) | 0.23 (0.24) |
| 18-month survival prediction | |||
| Overall | 356 | 0.68 (0.62–0.75) | 0.21 (0.24) |
| Solid organ | 333 | 0.67 (0.61–0.74) | 0.21 (0.24) |
| Lung | 116 | 0.65 (0.54–0.77) | 0.21 (0.23) |
| Breast | 58 | 0.68 (0.49–0.87) | 0.23 (0.24) |
| Liver | 37 | 0.79 (0.63–0.95) | 0.19 (0.24) |
| Hematologic malignancies | 23 | 0.63 (0.37–0.89) | 0.21 (0.21) |
| Kidney | 21 | 0.70 (0.45–0.96) | 0.20 (0.23) |
| Prostate | 19 | 0.65 (0.36–0.95) | 0.20 (0.23) |
| 24-month survival prediction | |||
| Overall | 356 | 0.67 (0.60–0.74) | 0.19 (0.22) |
| Solid organ | 333 | 0.66 (0.59–0.73) | 0.20 (0.21) |
| Lung | 116 | 0.62 (0.49–0.74) | 0.20 (0.21) |
| Breast | 58 | 0.71 (0.52–0.90) | 0.23 (0.25) |
| Liver | 37 | 0.76 (0.56–0.96) | 0.17 (0.21) |
| Hematologic malignancies | 23 | 0.63 (0.39–0.90) | 0.21 (0.22) |
| Kidney | 21 | 0.72 (0.47–0.97) | 0.20 (0.23) |
| Prostate | 19 | 0.75 (0.51–0.99) | 0.19 (0.23) |
Solid-organ malignancies indicated all kinds of malignancies but excluded hematopoietic malignancies. Some of the c-indices and their 95% confidence intervals were not available as no or only 1 patient died at the time point.
NA = not available.